AR048073A2 - 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene - Google Patents

40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene

Info

Publication number
AR048073A2
AR048073A2 ARP050100744A ARP050100744A AR048073A2 AR 048073 A2 AR048073 A2 AR 048073A2 AR P050100744 A ARP050100744 A AR P050100744A AR P050100744 A ARP050100744 A AR P050100744A AR 048073 A2 AR048073 A2 AR 048073A2
Authority
AR
Argentina
Prior art keywords
rapamycin
pharmaceutical composition
hidroxi
etil
production
Prior art date
Application number
ARP050100744A
Other languages
English (en)
Original Assignee
Novarits Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048073(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novarits Ag filed Critical Novarits Ag
Publication of AR048073A2 publication Critical patent/AR048073A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a 40-O-(2-hidroxi-etil)-rapamicina en forma cristalina no solvatada, proceso para producirla en forma sustancialmente pura, que comprende cristalizar 40-O-(2-hidroxi-etil)-rapamicina a partir de un medio de contiene el cristal y recuperar los cristales así obtenidos, y composicion farmacéutica que la comprende.
ARP050100744A 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene AR048073A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR048073A2 true AR048073A2 (es) 2006-03-29

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP1743657A3 (es)
JP (3) JP3805625B2 (es)
KR (2) KR100695834B1 (es)
CN (2) CN1876657B (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2732620C (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ303006B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU230174B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY127579A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL196627B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK287325B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI248938B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
JP4261365B2 (ja) 2002-02-13 2009-04-30 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 生物学的物質からのマクロライドの抽出方法
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ATE378345T1 (de) 2003-07-24 2007-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur aufreinigung von makroliden
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005056103A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP1962819A1 (en) * 2005-12-20 2008-09-03 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
US8492400B2 (en) * 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
JP2013529224A (ja) * 2010-06-07 2013-07-18 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
WO2017038612A1 (ja) * 2015-08-28 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1998004279A1 (en) * 1996-07-30 1998-02-05 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
EP1743657A3 (en) 2007-03-28
HK1038889A1 (en) 2002-04-04
ES2288033T3 (es) 2007-12-16
US6605613B2 (en) 2003-08-12
AU1657300A (en) 2000-06-26
CA2351580C (en) 2012-03-20
TR200201428T2 (tr) 2002-12-23
CA2732620A1 (en) 2000-06-15
JP2005200429A (ja) 2005-07-28
ITMI992520A0 (it) 1999-12-02
ID29250A (id) 2001-08-16
BE1012869A3 (fr) 2001-04-03
US7572804B2 (en) 2009-08-11
EP2279751A2 (en) 2011-02-02
HU230174B1 (hu) 2015-09-28
FR2786771A1 (fr) 2000-06-09
CA2351580A1 (en) 2000-06-15
KR100695834B1 (ko) 2007-03-19
AR054444A2 (es) 2007-06-27
BR9915986A (pt) 2001-09-04
RU2243769C2 (ru) 2005-01-10
TWI270550B (en) 2007-01-11
TWI248938B (en) 2006-02-11
CZ20012001A3 (cs) 2001-09-12
TR200101416T2 (tr) 2002-01-21
SK286688B6 (sk) 2009-03-05
NO20012424D0 (no) 2001-05-16
PE20001333A1 (es) 2000-12-12
US6852729B2 (en) 2005-02-08
HUP0104489A3 (en) 2004-05-28
NZ527781A (en) 2004-11-26
PT1137439E (pt) 2007-09-25
MY127579A (en) 2006-12-29
NZ511936A (en) 2003-10-31
JP3805625B2 (ja) 2006-08-02
PL348333A1 (en) 2002-05-20
PL208854B1 (pl) 2011-06-30
CN1876657A (zh) 2006-12-13
NO20121113L (no) 2001-05-16
WO2000033878A2 (en) 2000-06-15
DE69936352D1 (de) 2007-08-02
MY120594A (en) 2005-11-30
CA2651609A1 (en) 2000-06-15
HUP0104489A2 (hu) 2002-03-28
DE69936352T3 (de) 2012-05-03
US20080161334A1 (en) 2008-07-03
EP2269651A2 (en) 2011-01-05
CN1876657B (zh) 2013-01-09
KR20060096477A (ko) 2006-09-11
US20050107418A1 (en) 2005-05-19
CO4980847A1 (es) 2000-11-27
SK7662001A3 (en) 2001-12-03
DK1137439T3 (da) 2007-09-10
SG151072A1 (en) 2009-06-29
US20020032213A1 (en) 2002-03-14
JP5043308B2 (ja) 2012-10-10
CN1374872A (zh) 2002-10-16
ATE365051T1 (de) 2007-07-15
SI1137439T2 (sl) 2012-05-31
CY1106870T1 (el) 2012-09-26
KR20010101128A (ko) 2001-11-14
EP1137439B2 (en) 2011-11-23
SI1137439T1 (sl) 2008-06-30
ITMI992520A1 (it) 2001-06-02
ZA200104360B (en) 2002-01-16
JP2006111637A (ja) 2006-04-27
WO2000033878A3 (en) 2000-11-02
HK1038889B (en) 2008-01-25
CZ303006B6 (cs) 2012-02-22
US20030191148A1 (en) 2003-10-09
GB9826882D0 (en) 1999-01-27
ES2288033T5 (es) 2012-04-10
AR026102A1 (es) 2003-01-29
EP1743657A2 (en) 2007-01-17
DE69936352T2 (de) 2008-02-14
DK1137439T4 (da) 2012-03-19
AU759219B2 (en) 2003-04-10
NO334612B1 (no) 2014-04-22
CZ302210B6 (cs) 2010-12-22
US20090270441A1 (en) 2009-10-29
PL196627B1 (pl) 2008-01-31
IT1319701B1 (it) 2003-10-27
US7741338B2 (en) 2010-06-22
EP2279751A3 (en) 2011-02-16
HU228939B1 (en) 2013-07-29
US7297703B2 (en) 2007-11-20
FR2786771B1 (fr) 2002-12-27
IL143092A0 (en) 2002-04-21
GB9904934D0 (en) 1999-04-28
JP5165199B2 (ja) 2013-03-21
NO332698B1 (no) 2012-12-10
EP1137439A2 (en) 2001-10-04
CA2732620C (en) 2013-08-06
EP1137439B1 (en) 2007-06-20
SK287325B6 (sk) 2010-07-07
CN1261163C (zh) 2006-06-28
TW200540179A (en) 2005-12-16
JP2002531527A (ja) 2002-09-24
EP2269651A3 (en) 2011-03-09
NO20012424L (no) 2001-05-16

Similar Documents

Publication Publication Date Title
ES2066408T3 (es) Metodo para purificar bisfenol-a.
DE602004019881D1 (de) Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
ATE422386T1 (de) Verfahren zur herstellung von zeolith-folie deca- dodecasil 3r, zeolith-folie deca-dodecasil 3r und verbund-zeolith-folie deca-dodecasil 3r sowie herstellungsverfahren dafür
MY142926A (en) Method of the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
FI952065A0 (fi) Foerfarande foer tillvaratagande av en kristalliserbar organisk foerening
AR061516A1 (es) Composicion de rebaudiosido a y metodo para purificar el rebaudiosido a
BR0308292A (pt) Processo para aperfeiçoar a pureza e o rendimento da sucralose
TW200726794A (en) Method for producing cellulose ester film, polarizing plate and liquid crystal display
AR026102A1 (es) Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
TW200700482A (en) Cellulose ester film, manufacturing method thereof, optical film, polarizing plate and liquid crystal display
MX173709B (es) Un metodo para desarrollar cristales de enzimas
MY126071A (en) Crystalline form ii of cabergoline.
ECSP034927A (es) Método de síntesis técnica para la producción de tropenol
EP1623982A4 (en) METHOD FOR PRODUCING DOCETAXEL TRIHYDRATE
DE60027877D1 (de) Verfahren zur schnellen herstellung von crystallen mit wünschenswerter morphologie
ATE523490T1 (de) Verfahren zur herstellung von pleuromutilinen
HUP9701747A2 (hu) Eljárás zeolitok előállítására alkáli-alumínium-hidroszilikát-tartalmú nyersanyagokból
ATE480530T1 (de) Herstellungsverfahren für optisch aktive verbindungen
EP1693397A4 (en) PROCESS FOR PREPARING POLYHYDROALKANOATE CRYSTAL
BR0214971A (pt) Processo para a produção de um imunossupressor
FI20001655A0 (fi) Kiteytysmenetelmä
ATE357426T1 (de) Säulenförmige kristalle von 6-hydroxy-2-naphthyl säure und ein verfahren zu ihrer herstellung
ATE466010T1 (de) Verfahren zur herstellung von candesartan
ATE486867T1 (de) Verfahren zur herstellung von hochreinem meloxicam und meloxicam-kaliumsalz

Legal Events

Date Code Title Description
FG Grant, registration